What are Dopamine D2 receptor agonist drugs?

Dopamine D2 receptor agonist drugs are pharmacologic agents that share a common mechanism (typically targeting Dopamine D2 receptor). 1 are currently marketed, with 3 more in clinical development.

What are the marketed Dopamine D2 receptor agonist drugs?

Marketed Dopamine D2 receptor agonist drugs include Cabergoline Pill.

Dopamine D2 receptor agonist

1 marketed 3 in Phase 3

This page covers all Dopamine D2 receptor agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine D2 receptor.

Targets

Dopamine D2 receptor

Marketed (1)

Cabergoline Pill · Fertility Center of Las Vegas · Endocrinology / Reproductive Medicine
Cabergoline is a dopamine D2 receptor agonist that suppresses prolactin secretion from the pituitary gland.

Phase 3 pipeline (3)

Cabergoline tablets · Changchun GeneScience Pharmaceutical Co., Ltd. · Endocrinology
Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland.
Bromocriptine mesylate tablets · Changchun GeneScience Pharmaceutical Co., Ltd. · Endocrinology
Bromocriptine mesylate is a dopamine D2 receptor agonist that inhibits prolactin secretion and modulates hypothalamic-pituitary function.
Bromocriptine-QR · University of North Carolina, Chapel Hill · Endocrinology / Cardiovascular
Bromocriptine-QR is a quick-release formulation of bromocriptine, a dopamine D2 receptor agonist that reduces prolactin secretion and modulates circadian rhythm regulation.